Amylin Wins Restraining Order On Lilly Drug Sales

Law360, New York (May 26, 2011, 1:39 PM EDT) -- Amylin Pharmaceuticals Inc. said Thursday that a California federal judge had temporarily blocked Eli Lilly & Co. from using the same sales force to sell Amylin's diabetes treatment and a rival one produced by Boehringer Ingelheim GmbH, in a fight over a marketing agreement.

U.S. District Judge Janis L. Sammartino found that Amylin has sufficiently made a case that Lilly sales representatives tasked with promoting and selling Amylin's Type 2 diabetes treatment exenatide as part of an alliance between the two companies had been exposed to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.